-
The British Journal of Oral &... Feb 2019Ameloblastic carcinoma is an extremely rare, aggressive, malignant tumour that is most common in the mandible. Because of its rarity there is no general approach to...
Ameloblastic carcinoma is an extremely rare, aggressive, malignant tumour that is most common in the mandible. Because of its rarity there is no general approach to treatment. We present a rare case of an ameloblastic carcinoma with multiple metastases in a 63-year-old Japanese man that was treated in several different ways, including chemoradiotherapy and immunotherapy.
Topics: Ameloblastoma; Humans; Male; Mandible; Mandibular Neoplasms; Middle Aged
PubMed: 30600107
DOI: 10.1016/j.bjoms.2018.12.005 -
Oral Surgery, Oral Medicine, Oral... Dec 2010Malignant variants of ameloblastoma include metastasizing ameloblastoma, which microscopically appears benign but has metastasized and ameloblastic carcinoma that...
Malignant variants of ameloblastoma include metastasizing ameloblastoma, which microscopically appears benign but has metastasized and ameloblastic carcinoma that exhibits malignant histopathologic features. Ameloblastic carcinoma is classified into 2 types: a primary odontogenic malignancy and a secondary type resulting from malignant transformation of ameloblastoma. Most secondary ameloblastic carcinomas result from malignant transformation of a primary lesion after repeated postsurgical recurrences. Therefore it is rare to find an untreated secondary type presenting with histologic features of malignant transformation from an earlier benign lesion. We experienced a rare case of ameloblastic carcinoma, secondary type which might arise in an untreated ameloblastoma. The mechanism by which a preexisting benign ameloblastoma goes through a malignant transformation is also described.
Topics: Adult; Ameloblastoma; Biopsy; Cell Transformation, Neoplastic; Humans; Ki-67 Antigen; Male; Mandibular Neoplasms; Odontogenic Tumors; Radiography, Panoramic; Tomography, X-Ray Computed; Tumor Suppressor Protein p53
PubMed: 21112523
DOI: 10.1016/j.tripleo.2010.08.018 -
Oral Surgery, Oral Medicine, Oral... Nov 2014Ameloblastic carcinoma is a rare malignant odontogenic tumor. Here we present a case of a large ameloblastic carcinoma, which developed in a preexisting ameloblastoma in...
OBJECTIVE
Ameloblastic carcinoma is a rare malignant odontogenic tumor. Here we present a case of a large ameloblastic carcinoma, which developed in a preexisting ameloblastoma in the right submandibular region.
STUDY DESIGN
The patient was an 84-year-old woman who had received several surgical procedures for ameloblastoma, including a segmental mandibulectomy. The dimensions of the tumor were 12 × 8 × 5 cm, and both benign ameloblastoma and ameloblastic carcinoma were observed histologically. Based on histologic diagnosis, immunohistochemical staining and sequence analysis for p53 were performed.
RESULTS
Overexpression of p53 was observed only in the ameloblastic carcinoma. Additionally, a mutation of the p53 gene (TP53) in exon 5 was found by sequence analysis in the ameloblastic carcinoma.
CONCLUSIONS
This is the first case of ameloblastic carcinoma with a mutation of the p53 gene that has been associated with carcinomatous transformation.
Topics: Aged, 80 and over; Ameloblastoma; Diagnostic Imaging; Female; Genes, p53; Humans; Immunohistochemistry; Mandibular Neoplasms; Mutation; Odontogenic Tumors
PubMed: 24906942
DOI: 10.1016/j.oooo.2014.03.021 -
The Journal of Laryngology and Otology Oct 1995Ameloblastic carcinoma is an unusual tumour. There have been a total of 34 cases of ameloblastic carcinoma in the English literature to date. Of these only 11 cases have...
Ameloblastic carcinoma is an unusual tumour. There have been a total of 34 cases of ameloblastic carcinoma in the English literature to date. Of these only 11 cases have occurred in the maxilla. The authors report the 12th such case. The histological classification for odontogenic carcinoma has been debated for many years and recently revised, thus differentiating between malignant ameloblastoma and ameloblastic carcinoma. The authors review the current literature regarding diagnosis and treatment of this unusual lesion, and support the use of the term malignant ameloblastoma for the tumours that metastasize in spite of their benign histological appearance, whereas, the ameloblastic carcinoma is referred to as the primary tumour with malignant transformation, regardless of its metastatic potential.
Topics: Aged; Aged, 80 and over; Female; Humans; Maxillary Sinus Neoplasms; Odontogenic Tumors
PubMed: 7499939
DOI: 10.1017/s0022215100131925 -
Journal of the Korean Association of... Feb 2016Ameloblastic carcinoma is a malignant form of ameloblastoma defined by histological evidence of malignancy in primary, recurrent, or metastatic tumor. Such a tumor is...
Ameloblastic carcinoma is a malignant form of ameloblastoma defined by histological evidence of malignancy in primary, recurrent, or metastatic tumor. Such a tumor is rare, and the maxilla is an unusual site. Due to its rarity, the characteristics of this tumor in the maxilla have not been well described. Case 1: A 55-year-old, ill-appearing Nigerian male presented to our center with left maxillary swelling of seven-year duration. The swelling had been slow-growing and painless until one year prior, when the growth became rapid and was coupled with severe pain. The swelling affected both oral function and facial esthetics, and the patient reported difficulty breathing. There was a maxillary, ulcerated swelling extending from teeth 12 to 18 and blocking the left nostril. The involved teeth were moderately mobile. Case 2: A 32-year-old male farmer presented with recurrent right maxillary swelling of six-year duration. Prior to this episode, he had undergone surgery for ameloblastoma (follicular type). The present swelling was fungating through the skin and protruding into the right nostril. Ameloblastic carcinoma is an aggressive odontogenic tumor that requires aggressive surgical treatment.
PubMed: 26904494
DOI: 10.5125/jkaoms.2016.42.1.43 -
Indian Journal of Cancer 2015
Topics: Ameloblastoma; Biomarkers, Tumor; Carcinoma; Humans; Pathology, Molecular
PubMed: 26853419
DOI: 10.4103/0019-509X.175823 -
Journal of Oral and Maxillofacial... May 2011Epithelial odontogenic tumors arise from odontogenic epithelial structures. Malignant epithelial odontogenic tumors are extremely rare. Ameloblastic carcinomas may...
Epithelial odontogenic tumors arise from odontogenic epithelial structures. Malignant epithelial odontogenic tumors are extremely rare. Ameloblastic carcinomas may present denovo, ex ameloblastoma or ex odontogenic cyst. Most ameloblastic carcinomas are presumed to present denovo. To date less than 45 cases of ameloblastoma with metastasis have been reported. It occurs primarily in the mandible in a wide range of age groups; no sex or race predilection has been noted. It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption, and tooth mobility. The lesion is usually found unexpectedly after an incisional biopsy or the removal of a cyst. Histologic features of ameloblastic carcinoma shows tumor cells that resemble the cells seen in ameloblastoma, but they show cytologic atypia. Moreover, they lack the characteristic arrangement seen in ameloblastoma. The clinical course of ameloblastic carcinoma is typically aggressive, with extensive local destruction. Here we describe a rare case of ameloblastic carcinoma (secondary dedifferentiated carcinoma) of mandible in a 40-year-old female patient. Ameloblastic carcinoma: Secondary dedifferentiated carcinoma of the mandible.
PubMed: 22529581
DOI: 10.4103/0973-029X.84501 -
BMJ Case Reports Apr 2011Ameloblastic carcinoma is a rare aggressive malignant epithelial odontogenic tumour seen in a wide range of age group with no sex predilection. Patient usually presents...
Ameloblastic carcinoma is a rare aggressive malignant epithelial odontogenic tumour seen in a wide range of age group with no sex predilection. Patient usually presents with a rapidly enlarging swelling. It usually involves the posterior portion of the mandible. Treatment of choice is surgical removal of tumour followed by radiotherapy. We present a case of ameloblastic carcinoma in a 35-year-old man.
Topics: Adult; Ameloblastoma; Diagnosis, Differential; Humans; Male; Mandible; Mandibular Neoplasms; Tomography, X-Ray Computed
PubMed: 22701023
DOI: 10.1136/bcr.01.2011.3678 -
Oral Surgery, Oral Medicine, Oral... Dec 2011Ameloblastic carcinoma combines the histologic features of ameloblastoma with cytologic atypia, regardless of whether it has metastasized. Because of its rarity, there... (Comparative Study)
Comparative Study
OBJECTIVE
Ameloblastic carcinoma combines the histologic features of ameloblastoma with cytologic atypia, regardless of whether it has metastasized. Because of its rarity, there are few immunoprofile studies of ameloblastic carcinoma and few comparative studies of ameloblastic carcinoma and ameloblastoma. In this study, we compared the expression levels of cytokeratins (CKs), matrix metalloproteinases (MMPs), and Ki-67 between ameloblastoma and ameloblastic carcinoma, and assessed the usefulness of these markers for differentiating the tumors.
STUDY DESIGN
We assessed CK7, CK14, CK18, CK19, MMP-2, MMP-9, and Ki-67 expression by immunohistochemistry in 10 cases of ameloblastoma and 7 cases of ameloblastic carcinoma and then compared expression patterns between the 2 groups.
RESULTS
Immunostaining for CK14 and CK19 was diffuse and strongly positive in both tumor types, but staining for CK7 was focally positive in only 1 case of ameloblastoma and absent in all cases of ameloblastic carcinoma. However, there was a significant difference in CK18 expression between the 2 tumors (P = .000). Whereas 80% of ameloblastomas showed negative reactivity for CK18, most cases of ameloblastic carcinomas showed a moderate to strong intensity of immunostaining for CK18. Regarding the expression of MMPs, there were significant differences in parenchymal MMP-2 and stromal MMP-9 expression between the 2 tumors. Compared to ameloblastoma, ameloblastic carcinoma showed significantly strong expression of MMP-2 in parenchymal cells (P = .001) and MMP-9 in stromal cells (P = .013). However, there were no differences in MMP-2 expression of stromal cells and MMP-9 expression of parenchymal cells between ameloblastoma and ameloblastic carcinoma. The mean Ki-67 labeling index (LI) of ameloblastic carcinomas was 17.21%, which was significantly higher than that of ameloblastomas (3.57%; P = .002).
CONCLUSIONS
The significant expression of CK18, parenchymal MMP-2, stromal MMP-9, and Ki-67 could provide useful markers for differentiating ameloblastic carcinoma from ameloblastoma.
Topics: Adult; Aged; Ameloblastoma; Biomarkers, Tumor; Chromogenic Compounds; Female; Humans; Immunoenzyme Techniques; Immunohistochemistry; Keratin-14; Keratin-18; Keratin-19; Keratin-7; Ki-67 Antigen; Male; Mandibular Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Maxillary Neoplasms; Middle Aged; Odontogenic Tumors
PubMed: 22014999
DOI: 10.1016/j.tripleo.2011.06.036 -
Oral Surgery, Oral Medicine, Oral... May 2014Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This...
OBJECTIVE
Ameloblastic carcinoma often poses diagnostic challenges in its separation from benign ameloblastoma with atypical cytologic features or an unusual clinical course. This study aimed to determine whether SOX2 (sex determining region-Y-related high mobility group box 2), a protein expressed in the epithelial basal proliferative zone in dentigerous cysts, is a marker for ameloblastic carcinoma as well as for high-grade transformation in ameloblastic neoplasms.
STUDY DESIGN
Immunoperoxidase stains were performed according to a standard protocol. Immunostains were interpreted independently by 3 pathologists, and scores were recorded based on the percentage of staining and intensity of staining in the cells of interest.
RESULTS
The diffuse strong nuclear staining pattern has 86.4% specificity (19 of 22) to indicate the presence of high-grade features and has 76.9% sensitivity (10 of 13) in comparison with benign counterparts (P = .0021). Although previously shown as a marker for ameloblastic neoplasms, calretinin is weakly positive in a few cells in 50% (5 of 10) of ameloblastic carcinoma and 43% (3 of 7) of benign ameloblastic neoplasms, with little value in highlighting the high-grade change (P = .36).
CONCLUSIONS
The diffuse nuclear staining pattern of SOX2 is suggestive of a high-grade process in ameloblastic neoplasms. Numerous aggregates of cells harboring dense nuclear stain should raise concern for a malignancy.
Topics: Ameloblastoma; Biomarkers, Tumor; Humans; Immunoenzyme Techniques; Jaw Neoplasms; Microscopy, Fluorescence; SOXB1 Transcription Factors; Sensitivity and Specificity
PubMed: 24603057
DOI: 10.1016/j.oooo.2014.01.017